COMFORT-II Phase III Trial of Splenomegaly Reduction with Ruxolitinib in Myelofibrosis


COMFORT-II Phase III Trial of Splenomegaly Reduction with Ruxolitinib in Myelofibrosis
Slides from a presentation at ASH 2011 and transcribed comments from recent interviews with Hagop M Kantarjian, MD (1/13/12) and Srdan Verstovsek, MD, PhD (1/25/12)

Harrison CN et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT-II study. Proc ASH 2011;Abstract 279.

Dr Kantarjian is Chairman and Professor in the Leukemia Department at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Dr Verstovsek is Associate Professor, Chief of the Section of Myeloproliferative Neoplasms and Director of the Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center in Houston, Texas.